Amylyx Pharmaceuticals, Inc. (AMLX) vs Kiniksa Pharmaceuticals International, plc (KNSA)
- Amylyx Pharmaceuticals, Inc. AMLX 26.34 −4.74%
- Kiniksa Pharmaceuticals International, plc KNSA 78.59 −1.69%
Amylyx Pharmaceuticals, Inc. and Kiniksa Pharmaceuticals International, plc are both Drug Manufacturers Specialty & Generic companies. Kiniksa Pharmaceuticals International, plc is the larger, with a market value of $6.2B against $3.5B — 1.8× the size. Amylyx Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Kiniksa Pharmaceuticals International, plc trades at 73.4×. Kiniksa Pharmaceuticals International, plc grew revenue faster over the last twelve months: 58.9% against −77.1%. Kiniksa Pharmaceuticals International, plc has the higher net margin (9.59% vs 0.00%) and the higher return on invested capital (48.9% vs 0.00%). Across the 16 metrics below, Kiniksa Pharmaceuticals International, plc leads on 15 and Amylyx Pharmaceuticals, Inc. on 1.
Valuation
Profitability
| Metric | AMLX | KNSA | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | (42.65%) | 89.82% | 53.94% |
| Operating margin | 0.00% | 11.92% | 0.00% |
| Net margin | 0.00% | 9.59% | 0.00% |
| Free cash flow margin | 0.00% | 21.74% | 0.00% |
| Return on equity | (74.73%) | 14.04% | (0.40%) |
| Return on assets | (66.25%) | 10.36% | (3.32%) |
| Return on invested capital | 0.00% | 48.87% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack